Related references
Note: Only part of the references are listed.Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Arjan J. Kwakernaak et al.
ATHEROSCLEROSIS (2013)
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Nabil G. Seidah
CURRENT PHARMACEUTICAL DESIGN (2013)
Anti-PCSK9 therapies for the treatment of hypercholesterolemia
Amanda J. Hooper et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
Rachel M. DeVay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury
Maelle Le Bras et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2013)
Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects
Chan Joo Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
Heiner K. Berthold et al.
PLOS ONE (2013)
Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained
Ying Wu et al.
PLOS GENETICS (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
Hua Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
Ekaterina Chernogubova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
My road to Damascus: how I converted to the prohormone theory and the proprotein convertases
Michel Chretien
BIOCHEMISTRY AND CELL BIOLOGY (2012)
Moonlighting is mainstream: Paradigm adjustment required
Shelley D. Copley
BIOESSAYS (2012)
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kai Kysenius et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Antibodies to PCSK9 A Superior Way to Lower LDL Cholesterol?
Kara N. Maxwell et al.
CIRCULATION RESEARCH (2012)
Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration
Haruna Miyazawa et al.
CLINICA CHIMICA ACTA (2012)
Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
Payal Kohli et al.
CLINICAL CARDIOLOGY (2012)
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
Zuhier Awan et al.
CLINICAL CHEMISTRY (2012)
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
Liwen Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
Yascara Grisel Luna Saavedra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Vikas Sharotri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
Michael T. Lipari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Loss- and Gain-of-function PCSK9 Variants CLEAVAGE SPECIFICITY, DOMINANT NEGATIVE EFFECTS, AND LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) DEGRADATION
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The PCSK9 decade
Gilles Lambert et al.
JOURNAL OF LIPID RESEARCH (2012)
Metabolic Fingerprints of Serum, Brain, and Liver Are Distinct for Mice with Cerebral and Noncerebral Malaria: A 1H NMR Spectroscopy-Based Metabonomic Study
Soumita Ghosh et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Phase I Trial of bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell Vaccine (FANG) in Advanced Cancer
Neil Senzer et al.
MOLECULAR THERAPY (2012)
PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
Marie W. Lindholm et al.
MOLECULAR THERAPY (2012)
Automated design of ligands to polypharmacological profiles
Jeremy Besnard et al.
NATURE (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia
L. Pisciotta et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2012)
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Nabil G. Seidah et al.
PLOS ONE (2012)
Proprotein Convertase Subtilisin Kexin9 (PCSK9): A Novel Target For Cholesterol Regulation
Ajoy Basak et al.
PROTEIN AND PEPTIDE LETTERS (2012)
Statins Decrease Neuroinflammation and Prevent Cognitive Impairment after Cerebral Malaria
Patricia A. Reis et al.
PLOS PATHOGENS (2012)
Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogen Diet-induced Hypercholesterolemic Mice
Tsuyoshi Yamamoto et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Role of Proprotein Convertases in Prostate Cancer Progression
Frederic Couture et al.
NEOPLASIA (2012)
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates
Hong Liang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Clinical aspects of PCSK9
Bertrand Cariou et al.
ATHEROSCLEROSIS (2011)
Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
Oystein L. Holla et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
Janice Mayne et al.
CLINICAL CHEMISTRY (2011)
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo et al.
EMBO REPORTS (2011)
PCSK9: an emerging target for treatment of hypercholesterolemia
Christopher J. Duff et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
PC6 levels in uterine lavage are closely associated with uterine receptivity and significantly lower in a subgroup of women with unexplained infertility
Sophea Heng et al.
HUMAN REPRODUCTION (2011)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
Taichi Yamamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
Fen Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Adipose tissue remodeling and obesity
Kai Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
Oystein L. Holla et al.
JOURNAL OF LIPID RESEARCH (2011)
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage
Zacharie Taoufiq et al.
MALARIA JOURNAL (2011)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
Genetic deficiency for proprotein convertase subtilisin/kexin type 2 in mice is associated with decreased adiposity and protection from dietary fat-induced body weight gain
Y. Anini et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Yan G. Ni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Effects of the Prosegment and pH on the Activity of PCSK9 EVIDENCE FOR ADDITIONAL PROCESSING EVENTS
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Mali Liu et al.
JOURNAL OF LIPID RESEARCH (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes
Sanae Kourimate et al.
ATHEROSCLEROSIS (2009)
Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort
John F. Thompson et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Low- and High-Density Lipoproteins Modulate Function, Apoptosis, and Proliferation of Primary Human and Murine Pancreatic β-Cells
Sabine Ruetti et al.
ENDOCRINOLOGY (2009)
PCSK9 as a therapeutic target of dyslipidemia
Nabil G. Seidah
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Proprotein convertase subtilisin/kexin type 4 in mammalian fertility: a review
Charles Gyamera-Acheampong et al.
HUMAN REPRODUCTION UPDATE (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adverse Effects of Statins - Mechanisms and Consequences
Jerzy Beltowski et al.
CURRENT DRUG SAFETY (2009)
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
Vivienne M. Homer et al.
ATHEROSCLEROSIS (2008)
Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
Yasuko Miyake et al.
ATHEROSCLEROSIS (2008)
PCSK9: An enigmatic protease
Dayami Lopez
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2008)
Genetic Loci Associated With Plasma Concentration of Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, Triglycerides, Apolipoprotein A1, and Apolipoprotein B Among 6382 White Women in Genome-Wide Analysis With Replication
Daniel I. Chasman et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2008)
Inhibition of PCSK9 as a Novel Strategy for the Treatment of Hypercholesterolemia
Dayami Lopez
DRUG NEWS & PERSPECTIVES (2008)
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
Mary Cabell Jonas et al.
EMBO REPORTS (2008)
Proprotein convertases as therapeutic targets
Michel Chretien et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans
Thilina Dewpura et al.
FEBS JOURNAL (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
PCSK9 function and physiology (vol 49, pg 1303, 2008)
Andrew S. Peterson et al.
JOURNAL OF LIPID RESEARCH (2008)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Cristen J. Willer et al.
NATURE GENETICS (2008)
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans
Sekar Kathiresan et al.
NATURE GENETICS (2008)
Molecular population genetics of PCSK9:: a signature of recent positive selection
Keyue Ding et al.
PHARMACOGENETICS AND GENOMICS (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Philippe Costet et al.
TRENDS IN BIOCHEMICAL SCIENCES (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population
Francine Sirois et al.
GENETIC TESTING (2008)
Evidence for Positive Selection in the C-terminal Domain of the Cholesterol Metabolism Gene PCSK9 Based on Phylogenetic Analysis in 14 Primate Species
Keyue Ding et al.
PLOS ONE (2007)
The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain
Eric N. Hampton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Timothy S. Fisher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The proprotein convertases are potential targets in the treatment of dyslipidemia
Nabil G. Seidah et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission and heterozygous female susceptibility to dietary fat
Majambu Mbikay et al.
DEVELOPMENTAL BIOLOGY (2007)
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nasha Nassoury et al.
TRAFFIC (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-offunction PCSK9 genetic polymorphisms
Majambu Mbikay et al.
MEDICAL HYPOTHESES (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Increased stress-induced analgesia in mice lacking the proneuropeptide convertase PC2
Gilles Croissandeau et al.
NEUROSCIENCE LETTERS (2006)
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor
Gilles Lambert et al.
ENDOCRINOLOGY (2006)
The proprotein convertase SKI-1/S1P - In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors
Antonella Pasquato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population
P Yue et al.
HUMAN MUTATION (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
J Cameron et al.
HUMAN MOLECULAR GENETICS (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse
R Essalmani et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels
P Stawowy et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
F Lalanne et al.
JOURNAL OF LIPID RESEARCH (2005)
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis
SN Chen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Inhibiting uterine PC6 blocks embryo implantation: An obligatory role for a proprotein convertase in fertility
GY Nie et al.
BIOLOGY OF REPRODUCTION (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
TP Leren
CLINICAL GENETICS (2004)
Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P - Processing of SREBP-2, ATF6, and a viral glycoprotein
P Pullikotil et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Moonlighting proteins: old proteins learning new tricks
CJ Jeffery
TRENDS IN GENETICS (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
L Calza et al.
AIDS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Functional characterization of Narc 1, a novel proteinase related to proteinase K
S Naureckiene et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2003)
Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects
XR Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Epithelial sodium channel/degenerin family of ion channels: A variety of functions for a shared structure
S Kellenberger et al.
PHYSIOLOGICAL REVIEWS (2002)
Global burden of cardiovascular diseases - Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization
S Yusuf et al.
CIRCULATION (2001)
Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene
J Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells -: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions
AM Khatib et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs
J Ye et al.
MOLECULAR CELL (2000)
Identification of a novel consensus sequence at the cleavage site of the lassa virus glycoprotein
O Lenz et al.
JOURNAL OF VIROLOGY (2000)
Biosynthesis and enzymatic characterization of human SKI-1/S1P and the processing of its inhibitory prosegment
BB Touré et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age
M Cnop et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
